News

Teva Pharmaceuticals announced two new inhalers, the AirDuo Respiclick (fluticasone propionate and salmeterol) and its authorized generic.  These inhalers are both breath-activated inhalers that do not use spacers.   The availability of a generic inhaled corticosteroid and long acting bronchodilator offers generic treatment options for asthma.

AirDuo Launch Press Release.pdf

The latest Hot Topics article review is available on our website: Virtual Teach-To-Goal Adaptive Learning of Inhaler Technique for Inpatients with Asthma or COPD 

This study is the first to validate and demonstrate the efficacy of a self-directed personalized virtual learning tool, V-TTG TM, to teach inhaler technique. Because prior in-person educational interventions were limited in time and settings, this strategy that can first be used in the hospital and then repeated at home for reinforcement of the education addressed these important limitations. 

New from AAN: What parents need to know about peanut allergy guidelines.
Matt Greenhawt, MD, explains what the new NIAID guidelines recommend and what types of peanut-containing foods should be given to infants and young children.
Watch Now

Learn something new in 2017! Did you know that the Agency for Healthcare Research and Quality (#AHRQ) offers free CE/CME resources for health care professionals including members of AAE? Click here to see continuing-education credit learning activities.  http://ce.ahrq.gov/pcor/

Events are added periodically to our new calendar of events section of our website. You can view the list of events, or toggle to "Calendar View" for your convenience.

Check back often for new updates on Asthma Education. You can submit events to admin@asthmaeducators.org for review and posting

Be sure to check out the Hot Topics article reviews under our Education section of the website. Several new article are posted that you might have missed. Also, feel free to use Facebook or our Forums section to start a discussion about these important subjects. Our number of followers and the network of associations that are sharing our posts and engaging in our discussions continues to grow rapidly. Let's share as much as we can!

• NEW! Association of Sugar Sweetened Beverage Intake Frequency and Asthma Among US Adults
• NEW! Risk Factors Associated with 30-Day Asthma Readmissions
• Association between Asthma and Autism Spectrum Disorder: A Meta-Analysis
• Inhaler Technique in Children with Asthma: A Systematic Review
• Asthma Action Plan Receipt Among Children with Asthma 2 - 17 Years of Age
• Asthma as a Risk Factor for Zoster in Adults
• 
  

The AAE 2017 Board of Directors Election has now closed. Thank you to everyone who voted! Results will be announced soon.

Sulaiman et al¹  recently published an observational study that showed that only 20% of subjects used their inhalers correctly.   Many of the doses were either not taken on time or were inhaled incorrectly.  This article provides the asthma educator with more information about common errors which will allow for improved identification and remediation of these errors.

¹Sulaiman I, Seheult J, MacHale E, et al.  Irregular and Ineffective: A Quantitative Observational Study of the Time and Technique of Inhaler Use.  J Allergy Clin Immunol Pract. 2016 Sep-Oct;4(5):900-909.

AAE invites all members to cast their votes for next year's Board of Directors. Short biographical information and statements have been compiled for each candidate along with a link to vote when ready. Please vote for no more than three candidates. 

Visit the voting page today. Elections will close October 31st so cast your vote soon!

Please Contact Us with any questions.

GlaxoSmithKline plc (GSK) today announced publication of results from the paediatric ‘LABA’ (long acting beta2-agonist) safety study, VESTRI (SAS115358) in the New England Journal of Medicine (NEJM). Headline results reported in March, demonstrated that the study had achieved its primary endpoint. The study compared Advair® Diskus®, a combination of the LABA, salmeterol and inhaled corticosteroid (ICS), fluticasone propionate (FP) to FP monotherapy, to assess the safety profiles of each medicine when used to treat children 4-11 years of age with asthma. This was assessed by the composite endpoint of serious asthma-related events (deaths, intubations or hospitalisations). These results are also being presented at the European Respiratory Society (ERS) International Congress in London, UK on 7th September, (Abstract number: OA4798).

The primary endpoint of the study showed the salmeterol/FP combination (FSC) twice-daily (100/50mcg, 250/50mcg) demonstrated non-inferiority compared to corresponding doses of FP twice-daily (100mcg, 250mcg), Hazard Ratio (HR) 1.285, (95% CI 0.726, 2.272) p=0.006 on the risk of serious asthma-related events.  In the study a non-statistically significant reduction of 14% was observed in the risk of time-to-first asthma exacerbation for FSC compared to FP (HR 0.859; 95% CI 0.729, 1.012). 

Kate Knobil, Chief Medical Officer - Pharmaceuticals at GSK said: “We are pleased that the study achieved its primary safety endpoint and has now been published in a key peer-reviewed journal as well as being presented at the forthcoming European Respiratory Society congress. These are important data, especially in an area where data are limited, such as in paediatric asthma.  We understand how important it is for clinicians to have access to data that have been independently reviewed, to give them greater knowledge and understanding in this disease area.”

Continue reading:

http://www.gsk.com/en-gb/media/press-releases/2016/nejm-publishes-results-of-gsk-s-long-term-laba-safety-study-of-advair-diskus-in-children-aged-4-11-years-with-asthma/